1610758-19-4 Usage
Description
C35H43N7O5, also known as O-Desethyl O-Isopropyl Dabigatran Etexilate, is an impurity found in Dabigatran Etexilate Mesylate (D100150). Dabigatran Etexilate Mesylate is a nonpeptide, direct thrombin inhibitor and an antithrombotic agent. The compound C35H43N7O5 is a derivative of Dabigatran Etexilate, which is used in the pharmaceutical industry for its potential therapeutic properties.
Uses
Used in Pharmaceutical Industry:
C35H43N7O5 is used as an impurity in the production of Dabigatran Etexilate Mesylate for its potential role in antithrombotic therapy. As an impurity, it may have an impact on the efficacy and safety of the final drug product, and thus, its presence is closely monitored during the manufacturing process.
Used in Research and Development:
C35H43N7O5 is used as a research compound to study the properties and effects of Dabigatran Etexilate Mesylate. Understanding the behavior of this impurity can help in optimizing the manufacturing process and improving the overall quality of the antithrombotic agent.
Used in Quality Control:
C35H43N7O5 is used as a reference compound in quality control testing for Dabigatran Etexilate Mesylate. By comparing the properties of the drug product with the known characteristics of the impurity, manufacturers can ensure that the final product meets the required standards for safety and efficacy.
Check Digit Verification of cas no
The CAS Registry Mumber 1610758-19-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,6,1,0,7,5 and 8 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1610758-19:
(9*1)+(8*6)+(7*1)+(6*0)+(5*7)+(4*5)+(3*8)+(2*1)+(1*9)=154
154 % 10 = 4
So 1610758-19-4 is a valid CAS Registry Number.
1610758-19-4Relevant articles and documents
Identification, synthesis, and strategy for the reduction of potential impurities observed in dabigatran etexilate mesylate processes
Zheng, Yong-Yong,Shen, Cheng-Wu,Zhu, Mei-Yu,Zhou, Yi-Meng,Li, Jian-Qi
, p. 744 - 750 (2014/07/08)
Synthetic impurities that are present in dabigatran etexilate mesylate were studied, and possible pathways by which these impurities are formed during the manufacturing process were examined. The impurities were monitored by high-performance liquid chromatography, and their structures were determined by mass spectrometry and 1H and 13C NMR. Potential causes for the formation of these impurities are discussed, and strategies to minimize their formation are also described.
